China's BCI Tech Steps Out of the Lab
Summary
A patient at Shanghai’s Huashan Hospital received the world’s first commercial implant of a regulator-approved invasive BCI on July 13 using Neuracle Technology’s NEO system, which decodes epidural signals to restore hand mobility via external devices. The NEO system had obtained Class III NMPA registration in March 2026, making it the first implantable BCI cleared for commercial prescription worldwide. The milestone signals China’s rapid move from experimental BCI research into clinical and commercial deployment.
Why it matters
China's transition from BCI research to commercial deployment — headlined by Neuracle's first regulator-approved implant — signals the country intends to be a serious competitor in a field long dominated by US companies.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial